Fish Matthew, Arkless Kate, Jennings Aislinn, Wilson Julie, Carter Michael J, Arbane Gill, Campos Sara, Novellas Neus, Wester Rianne, Petrov Nedyalko, Niazi Umar, Sanderson Barney, Ellis Richard, Saqi Mansoor, Spencer Jo, Singer Mervyn, Martinez-Nunez Rocio T, Pitchford Simon, Swanson Chad M, Shankar-Hari Manu
School of Immunology and Microbial Sciences, Kings College London, London, UK.
Department of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK.
J Intensive Care Soc. 2022 Aug;23(3):318-324. doi: 10.1177/1751143720966286. Epub 2020 Nov 6.
Sepsis is a common illness. Immune responses are considered major drivers of sepsis illness and outcomes. However, there are no proven immunomodulator therapies in sepsis. We hypothesised that in-depth characterisation of sepsis-specific immune trajectory may inform immunomodulation in sepsis-related critical illness. We describe the protocol of the IMMERSE study to address this hypothesis. We include critically ill sepsis patients without documented immune comorbidity and age-sex matched cardiac surgical patients as controls. We plan to perform an in-depth biological characterisation of innate and adaptive immune systems, platelet function, humoral components and transcriptional determinants of the immune system responses in sepsis. This will be done at pre-specified time points during their critical illness to generate an illness trajectory. The sample size for each biological assessment is different and is described in detail. In summary, the overall aim of the IMMERSE study is to increase the granularity of longitudinal immunology model of sepsis to inform future immunomodulation trials.
脓毒症是一种常见疾病。免疫反应被认为是脓毒症病情及预后的主要驱动因素。然而,目前尚无经证实的脓毒症免疫调节疗法。我们假设,对脓毒症特异性免疫轨迹进行深入表征可能为脓毒症相关危重症的免疫调节提供依据。我们描述了IMMERSE研究的方案以验证这一假设。我们纳入无免疫合并症记录的脓毒症危重症患者,并将年龄和性别匹配的心脏手术患者作为对照。我们计划对脓毒症患者的先天性和适应性免疫系统、血小板功能、体液成分以及免疫系统反应的转录决定因素进行深入生物学表征。这将在他们危重症期间的预先指定时间点进行,以生成病情轨迹。每项生物学评估的样本量不同,并已详细说明。总之,IMMERSE研究的总体目标是提高脓毒症纵向免疫学模型的精细度,为未来的免疫调节试验提供依据。